Current Neuro-Oncology
Volume
26 Number 24
31 October 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 24, 31 October
Figarella-Branger D, Colin C, Mokhtari K, Uro-Coste E, Idbaih A,
Appay R, Tabouret E, Touat M, Seyve A, Carpentier C, Dehais C,
Ducray F; POLA network.
Reappraisal of
prognostic factors in CNS WHO grade 3 oligodendrogliomas
IDH-mutant and 1p/19q co-deleted: lessons from the French POLA
cohort.
Neuro
Oncol. 2024 Oct 21:noae221. doi:
10.1093/neuonc/noae221. PMID:
39432559. Observational study˰
ˍ
Wetzel EA, Nohman AI, Hsieh AL, Reuss D, Unterberg AW, Eyüpoglu
IY, Hua L, Youssef G, Wen PY, Cahill DP, Jungk C, Juratli TA,
Miller JJ.
A multi-center, clinical
analysis of IDH-mutant gliomas, WHO Grade 4: implications for
prognosis and clinical trial design.
J
Neurooncol. 2024 Oct 21. doi:
10.1007/s11060-024-04852-7. PMID:
39432026. Observational study. ˍ
Marzouki S, De Vulder N, Dekeyzer S.
From
cerebellum to skeleton: a case report of SHH-activated
medulloblastoma with extraneural spread.
Acta
Neurol Belg. 2024 Oct 22. doi:
10.1007/s13760-024-02663-1. PMID:
39436558. Case report˰
ˍ
Wide A, Ahlgren J, Smedby KE, Hellman K, Henriksson R, Ståhl
O, Lampic C, Wettergren L.
Health-related
quality of life and supportive care needs in young adult cancer
survivors-a longitudinal population-based study.
Support
Care Cancer. 2024 Oct 22;32(11):742. doi:
10.1007/s00520-024-08896-3. PMID:
39436421. Observational study. ˍ
Cine HS, Uysal E, Gunaydin ME, Soguk E.
Dissecting
the Molecular Profile of Glioblastoma: Exploring the Influence of
Subventricular Zone Proximity.
Turk
Neurosurg. 2024 Oct 23. doi:
10.5137/1019-5149.JTN.45105-23.3. PMID:
39474960. Observational study. ˍ
Kirishima M, Yokoyama S, Akahane T, Higa N, Uchida H, Yonezawa H,
Matsuo K, Yamamoto J, Yoshimoto K, Hanaya R, Tanimoto A.
Prognosis prediction via histological
evaluation of cellular heterogeneity in glioblastoma.
Sci
Rep. 2024 Oct 23;14(1):24955. doi:
10.1038/s41598-024-76826-8. PMID:
39438642. Observational study. ˍ
*Knudsen AM, Ewald JD, Pedersen V, Haupt-Jorgensen M, Hansen EVR,
Kristensen BW.
Characterisation of the
tumour microenvironment in primary and recurrent glioblastomas.
Neuropathol
Appl Neurobiol. 2024 Oct 24;50(5):e13012. doi:
10.1111/nan.13012. PMID:
39449228. Observational study. ˍ
Bianconi A, Presta R, La Cava P, De Marco R, Zeppa P, Lacroce P,
Castaldo M, Bruno F, Pellerino A, Rudà R, Melcarne A,
Garbossa D, Bo M, Cofano F.
A novel
scoring system proposal to guide surgical treatment indications
for high grade gliomas in elderly patients: DAK-75.
Neurosurg
Rev. 2024 Oct 25;47(1):823. doi:
10.1007/s10143-024-03052-1. PMID:
39453521. Observational study˰
ˍ
Gottardo NG, Gajjar A.
Determining
Risk Features for Medulloblastoma in the Molecular Era.
Neuro
Oncol. 2024 Oct 25:noae223. doi:
10.1093/neuonc/noae223. PMID:
39450440. Comment. ˍ
Refers
to:
*Massimino M, Barretta F, Dossena C, Minasi S, Buttarelli
FR, Biassoni V, Oriani M, Schiavello E, Ficorilli M, Nigro O,
Pollo B, Antonelli M, Donofrio V, Maggioni M, Kool M, Pecori E,
Vennarini S, Giangaspero F, Gianno F, Erbetta A, Chiapparini L,
Luksch R, Barzanò E, Meazza C, Podda M, Spreafico F,
Terenziani M, Bergamaschi L, Ferrari A, Casanova M, Chiaravalli S,
Gattuso G, Modena P, Bailey S, De Cecco L.
Long-term
outcome of the Milano-HART strategy for high-risk medulloblastoma,
including the impact of molecular subtype.
Neuro
Oncol.
2024 Sep 27:noae189. doi:
10.1093/neuonc/noae189. PMID:
39331528. Observational study. ˍ
Nishiyama A, Sato S, Sakaguchi H, Kotani H, Yamashita K, Ohtsubo
K, Sekiya T, Watanabe A, Tajima A, Shimaguchi C, Mizuguchi K,
Ikeda H, Kinoshita M, Nakada M, Takeuchi S.
Pembrolizumab
efficacy in a tumor mutation burden-high glioblastoma patient: A
case study and implications for precision oncology.
Cancer
Sci. 2024 Oct 25. doi:
10.1111/cas.16370. PMID:
39453824. Case report. ˍ
Yamaguchi J, Ohka F, Seki M, Motomura K, Deguchi S, Shiba Y,
Okumura Y, Kibe Y, Shimizu H, Maeda S, Takido Y, Yamamoto R,
Nakamura A, Karube K, Saito R.
Dual
phenotypes in recurrent astrocytoma, IDH-mutant; coexistence of
IDH-mutant and IDH-wildtype components: a case report with genetic
and epigenetic analysis.
Acta
Neuropathol Commun. 2024 Oct 26;12(1):169. doi:
10.1186/s40478-024-01879-9. PMID:
39456052. Case report. ˍ
Azam A, Kurbegovic S, Carlsen EA, Andersen TL, Larsen VA, Law I,
Skjøth-Rasmussen J, Kjaer A.
Prospective
phase II trial of [68Ga]Ga-NOTA-AE105
uPAR-PET/MRI in patients with primary gliomas: Prognostic value
and Implications for uPAR-targeted Radionuclide Therapy.
EJNMMI
Res. 2024 Oct 29;14(1):100. doi:
10.1186/s13550-024-01164-9. PMID:
39472354. Interventional study. ˍ
Döring K, Malinova V, Bettag C, Rohde V, Schulz M, Menck K,
Bleckmann A, Binder C, Büntzel J.
The
Diagnostic Potential of Extracellular Vesicles Derived
From the Blood Plasma of Glioblastoma
Patients.
In
Vivo. 2024 Oct 29;38(6):2735-2739. doi:
10.21873/invivo.13752. PMID:
39477379. Observational study. ˍ
Jiang X, Xu XN, Yuan XY, Jiang HR, Zhao MJ, Duan YX, Li G.
The
apparent diffusion coefficient can serve as a predictor of
survival in patients with gliomas.
Radiat
Oncol. 2024 Oct 29;19(1):149. doi:
10.1186/s13014-024-02535-1. PMID:
39472956. Observational study. ˍ
Leppert J, Ditz C, Matschke J, Matone MV, Kuppler P, Hillbricht C,
Krenzlin H, Keric N, Schacht H, Ziemann C, Groh EM, Liubich L,
Zemskova O, Rades D, Löser A.
Preoperative
Tumor Growth Rate Does Not Predict Overall or Progression-free
Survival in Patients With Glioblastoma.
Anticancer
Res. 2024 Oct 29;44(11):5043-5049. doi:
10.21873/anticanres.17328. PMID:
39477314. Observational study.ˍ
Chen L, Rizk E, Sherief M, Chang M, Lucas CH, Bettegowda C, Croog
V, Mukherjee D, Rincon-Torroella J, Kamson DO, Huang P, Holdhoff
M, Schreck K.
Molecular
characterization of gliosarcoma reveals prognostic biomarkers and
clinical parallels with glioblastoma.
J
Neurooncol. 2024 Oct 30. doi:
10.1007/s11060-024-04859-0. PMID:
39476147. Observational study. ˍ
Pei Y, Jiang H, Zhang E, Xia B, Dong L, Dai Y.
Temporal
muscle thickness is not a prognostic predictor in patients with
high-grade glioma, an experience at two centers in China.
Open
Med (Wars). 2024 Oct 30;19(1):20241053. doi:
10.1515/med-2024-1053. PMID:
39479466. Observational study. ˍ
Shi ZF, Li KK, Kwan JS, Chung NY, Wong SC, Chu AW, Chen H, Chan
DT, Mao Y, Ng HK.
The molecular
history of IDH-mutant astrocytomas without adjuvant
treatment.
Brain
Pathol. 2024 Oct 30:e13300. doi:
10.1111/bpa.13300. PMID:
39473241. Observational study. ˍ
Tang PLY, Romero AM, Nout RA, van Rij C, Slagter C, Swaak-Kragten
AT, Smits M, Warnert EAH.
Amide proton
transfer-weighted CEST MRI for radiotherapy target delineation of
glioblastoma: a prospective pilot study.
Eur
Radiol Exp. 2024 Oct 30;8(1):123. doi:
10.1186/s41747-024-00523-4. PMID:
39477835. Interventional study. ˍ
Sarkaria JN, Ballman KV, Kizilbash SH, Sulman EP, Giannini C,
Friday BB, Butowski NA, Mohile NA, Piccioni DE, Battiste JD,
Drappatz J, Campian JL, Mashru S, Jaeckle KA, O'Brien BJ, Dixon
JG, Kabat BF, Laack NL, Hu LS, Kaufmann T, Kumthekar P, Ellingson
BM, Anderson SK, Galanis E.
Efficacy
of Adding Veliparib to Temozolomide for Patients With
MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
JAMA
Oncol. 2024 Oct 31:e244361. doi:
10.1001/jamaoncol.2024.4361. PMID:
39480453. Interventional study˰
ˍ
Spencer D, Bonner ER, Tor-Díez
C, Liu X, Bougher K, Prasad R, Gordish-Dressman H, Eze A, Packer
RJ, Nazarian J, Linguraru MG, Bornhorst M.
Tumor
volume
features predict survival outcomes for patients diagnosed with
diffuse intrinsic
pontine glioma.
Neurooncol
Adv. 2024 Aug
30;6(1):vdae151. doi:
10.1093/noajnl/vdae151. PMID:
39434924. Observational study. ˍ
Limon D, Amiel A, Even Haim S, Gordon N, Tschernichovsky R,
Stemmer S, Gal O, Laviv Y, Kanner A, Siegal T, Yust-Katz S.
A
phase II, open-label, single-arm trial of pembrolizumab for
recurrent meningioma and solitary fibrous tumor.
Neurooncol
Adv. 2024 Sep 16;6(1):vdae154. doi:
10.1093/noajnl/vdae154. PMID:
39429970. Interventional study. ˍ
Mergen E, Landrock S, Chizzali B.
Tumor
Treating Fields (TTFields) Therapy and Lomustine Chemotherapy for
the Treatment of Unresectable Progressive Glioblastoma.
Case
Rep Oncol. 2024 Sep 23;17(1):1056-1062. doi:
10.1159/000540669. PMID:
39474554. Case report. ˍ
Carrillo J, Gill JM, Redfern C, Babic I, Nomura N, Shah DK,
Carrick S, Kesari S.
A phase 1 dose
escalation of pritumumab in patients with refractory or recurrent
gliomas or brain metastases.
Neurooncol
Adv. 2024 Sep 30;6(1):vdae166. doi:
10.1093/noajnl/vdae166. PMID:
39465217. Interventional study. ˍ
Shen H, Mei Q, Chai X, Jiang Y, Liu A, Liu J.
The
prognostic significance of synchronous metastasis in glioblastoma
multiforme patients: a propensity score-matched analysis using
SEER data.
Front
Neurol. 2024 Oct 8;15:1429826. doi:
10.3389/fneur.2024.1429826. PMID:
39440248. Observational study. ˍ
Valerio JE, Wolf AL, Mantilla-Farfan P, Aguirre Vera GJ,
Fernández-Gómez MP, Alvarez-Pinzon AM.
Efficacy
and Cognitive Outcomes of Gamma Knife Radiosurgery in Glioblastoma
Management for Elderly Patients.
J
Pers Med. 2024 Oct 10;14(10):1049. doi:
10.3390/jpm14101049. PMID:
39452556. Observational study. ˍ
Gkasdaris G, Berthiller J, Guyotat J, Jouanneau E, Gallet C,
Meyronet D, Thomas L, Cartalat S, Seyve A, Honnorat J, Ducray F,
Picart T.
Is Carmustine Wafer
Implantation in Progressive High-Grade Gliomas a Relevant
Therapeutic Option? Complication Rate, Predictors of Complications
and Onco-Functional Outcomes in a Series of 53 Cases.
Cancers
(Basel). 2024 Oct 12;16(20):3465. doi:
10.3390/cancers16203465. PMID:
39456559. Observational study. ˍ
Gonçalves JM, Ferreira F, Carvalho B, Polónia P,
Linhares P.
Survival Determinants in
Glioblastoma: An Insight into Biopsy-Only Patient
Outcomes.
Biomedicines.
2024 Oct 13;12(10):2327. doi:
10.3390/biomedicines12102327. PMID:
39457639. Observational study. ˍ
He L, Chen M, Li H, Shi X, Qiu Z, Xu X.
Differentiation
between high-grade gliomas and solitary brain metastases based on
multidiffusion MRI model quantitative analysis.
Front
Oncol. 2024 Oct 14;14:1401748. doi:
10.3389/fonc.2024.1401748. PMID:
39469636. Observational study. ˍ
Gately L, Drummond K, Dowling A, Bennett I, Freilich R, Phillips
C, Ahern E, Campbell D, Dumas M, Campbell R, Harrup R, Kim GY,
Reeves S, Collins IM, Gibbs P.
Evolving
Practice and Outcomes in Grade 2 Glioma: Real-World Data from a
Multi-Institutional Registry.
Cancers (Basel). 2024
Oct 17;16(20):3514. doi:
10.3390/cancers16203514. PMID:
39456608. Observational study. ˍ
Pak O, Kosianova A, Zaitsev S, Sharma A, Sharma H, Bryukhovetskiy
I.
Valproic Acid and Celecoxib Enhance
the Effect of Temozolomide on Glioblastoma Cells.
CNS
Neurol Disord Drug Targets. 2024 Oct 18. doi:
10.2174/0118715273330268241008220702. PMID:
39428930. Laboratory investigation˰
ˍ
Yuzkan S, Karagulle M, Sam Ozdemir M, Mutlu S, Kocak B.
Predictive Value of T2*-Weighted
Perfusion and T1-Weighted Permeability MRI Parameters in
Determining IDH Mutation Status and Grade of Gliomas.
Turk
Neurosurg. 2024 Oct 18. doi:
10.5137/1019-5149.JTN.46251-24.3. PMID:
39474970. Observational study. ˍ
*Su J, Guo S, Chen Z, Han Y, Yan J, Tang Q, Mao Y, Zhang H, Hou G,
Dong G, Guo C, Yang P.
Efficacy of
various extent of resection on survival rates of patients with
pilocytic astrocytoma: based on a large population.
Sci
Rep. 2024 Oct 20;14(1):24646. doi:
10.1038/s41598-024-75751-0. PMID:
39428432. Observational study. ˍ